Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07450521 · ClinicalTrials.gov registry record · Phase 1
Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult Males
A Phase 1 study of Healthy Adult Male, sponsored by Mediar Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT07450521: Recruiting Phase 1 study of Healthy Adult Male, sponsored by Mediar Therapeutics.
NCT07450521 is a Phase 1 study of Healthy Adult Male that is actively recruiting participants, run by Mediar Therapeutics. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07450521, a Phase 1 study of Healthy Adult Male, is actively recruiting participants, sponsored by Mediar Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, and PK of MTX-463 when administered via SC injection in healthy adult males.
Primary Outcome
Unit of Measure: Nanogram·hour per milliliter (ng·h/mL)
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL MTX-463
Study Locations (1)
Utah
- Icon Slc Cru - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2026-02-18 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What NCT07450521 shows while recruiting
NCT07450521 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Healthy Adult Male appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07450521 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT07450521 about?
NCT07450521 is a clinical study titled "Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult Males". A randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, and PK of MTX-463 when administered via SC injection in healthy adult males.
What is the current status of trial NCT07450521?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2026-02-18. Estimated completion is 2026-03.
What conditions does trial NCT07450521 study?
This clinical trial studies the following conditions: Healthy Adult Male.
What interventions are being tested in trial NCT07450521?
The interventions under investigation include: Placebo (OTHER), MTX-463 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07450521?
This trial is sponsored by Mediar Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07450521 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07450521's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI